Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
The panel will discuss the value proposition for investing in women’s health.J.P. Morgan is hosting a three-panel women’s health series at this ...
Nasdaq25d
Daré Bioscience Initiates Phase 3 Study for Sildenafil Cream as Potential First FDA-Approved Treatment for Female Sexual Arousal Disorder
Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder ...
ADVFN8d
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
DARE Dare Bioscience Inc Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) ...
Yahoo Finance6d
Daré Bioscience, Inc. (DARE)
FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the ...
Yahoo Finance25d
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates ...
Stockhouse25d
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to ...
Mena FN25d
Daré Bioscience Announces Phase 3 Plans For Sildenafil Cream, 3.6%, In The Treatment Of Female Sexual Arousal Disorder (FSAD)
FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sil ...
Daré Bioscience, Inc.: Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sildenafil Cream has the potential to receive the first FDA ...